Synonyms: HMR1726; teriflunomide; (Z)-2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide; D09PUR; A77-1726 (monosodium salt); C12H9F3N2O2; CID3898; Teriflunomide (unspecified stereo); C12-H9-F3-N2-O2; CID444960; CID5479847; CS-O-05920; ANTIPROLIFERATIVE AGENT A771726; A 771726; B1850; T3287; C072876; C527525; 2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)-crotoneamide; (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-3-enamide; (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phe-nyl]-2-butenamide; 79902-63-9; A26; HMR-1726; SU 20; teriflunomida; teriflunomidum; A771726; RS 61980; A-771726; UNII-1C058IKG3B; Teriflunomide; CHEBI:68540; A 77-1726; 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; (Z)-2-cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-p-crotonotoluidide; 1C058IKG3B; N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide; (2z)-2-Cyano-3-Hydroxy-N-[4-(Trifluoromethyl)phenyl]but-2-Enamide; (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide; A77-1726; 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-; 163451-81-8; (2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile; 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-; 2-Cyano-3-OH-N-(4-trifluoromethylphenyl)croton amide; Teriflunomide [INN]; 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-; MFCD00910058; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide; Active metabolite of leflunomide; Teriflunomide [USAN:INN]; Teriflunamide; Flucyamide; 2-cyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]-2-butenamide; Malononitrilamide; Aubagio (TN); SU-0020; Leflunomide Impurity B; Teriflunomide (USAN); AC1NUIOH; RS-61980; 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide; AC1L1GYH; Aubagio; A 1726; AC1L9H6I; SCHEMBL22661; Teriflunomide(A-771726); Teriflunomide, A77 1726; GTPL6844; UTNUDOFZCWSZMS-YFHOEESVSA-N; 1185240-22-5; (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide; BDBM50018011; A77 1726; s4169; ZINC13512456; AKOS015994773; API0000341; CS-1031; DB08880; LE-0275; SB16822; AC-26446; AJ-63994; 108605-62-5; CC-10329; HY-15405; LS-46899; SC-90977; RT-011141; ST24036515; SW219377-1; Leflunomide-d4 Metabolite (Teriflunomide-d4); D10172; EN300-189832; HMR 1726; AB01565775_02; A801897; C-16971; J-010046; N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide; N-[4-(Trifluoromethyl)phenyl]-2-cyano-3-hydroxycrotonamide; (Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide; 2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile; 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, (Z)-; (2E)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile; HMR1726; (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide (Teriflunomide); 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide (E/Z)-mixture; Leflunomide Related Compound B, United States Pharmacopeia (USP) Reference Standard; (2Z)-3-oxidanylidene-2-[oxidanyl-[[4-(trifluoromethyl)phenyl]amino]methylidene]butanenitrile; N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide, 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-beuteamide, LEF-M; Simvistatin; CHEMBL973; D05LAR; D07QFP; D08TRA;